Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey

Morales-Soriano, Rafael; Esteve-Pérez, N.; Segura-Sampedro, Juan José; Cascales-Campos, P.A.; Barrios, P.; Alonso-Gómez, Jaime; García-Fadrique, Alfonso; Arjona‐Sánchez, Álvaro; Arteaga-Martín, X.; Bretcha-Boix, Pedro; Camps-Vilata, Bruno; Martin, Vittoria; García-Olmo, Damián; Gil-Martínez, José; Portilla, Alberto Gómez; González-Bayón, L.; González-Moreno, Santiago; Gutiérrez‐Calvo, Alberto; Martínez‐Regueira, Fernando; Mayol-Oltra, A.; Muñoz-Casares, Cristóbal; Padilla, David; Pacheco-Sánchez, D.; Parra-Baños, P.A.; Pereira-Pérez, Fernando; Pérez-Celada, Judit; Ramírez-Plaza, César Pablo; Ramos-Bernadó, I.; Torres-Meleroad, J.; Vaqué-Urbaneja, Javier

doi:10.1016/j.ejso.2017.11.012

Cited by 17 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Morales-Soriano et al analyzed the CRS + HIPEC procedure in 25 treatment centers for peritoneal cancer in Spain. The commonly used chemotherapeutic agents were platinum (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and mitomycin [31]. Either the structure or the function of neurons and glial cells is changed by platinum-based chemotherapeutics [32].…”

Section: Neuropathic Painmentioning

confidence: 99%

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Wang

2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment choice for peritoneal cancer. However, patients commonly suffer from severe postoperative pain. The pathophysiology of postoperative pain is considered to be from both nociceptive and neuropathic origins. Main body: The recent advances on the etiology of postoperative pain after CRS + HIPEC treatment were described, and the treatment strategy and outcomes were summarized. Conclusion: Conventional analgesics could provide short-term symptomatic relief. Thoracic epidural analgesia combined with opioids administration could be an effective treatment choice. In addition, a transversus abdominis plane block could also be an alternative option, although further studies should be performed.

show abstract

Section: Neuropathic Painmentioning

confidence: 99%

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Wang

2020

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In addition to the extreme variability of the drugs and temperatures used, there is no consensus on the HIPEC technique. In a recent review of the current practice in Spanish hospitals [20], 65% of the centers administered HIPEC using a closed system, as opposed to the open system used for example in the Van Driel study, were the debulked cavity is left open. 53% of the surgeons indicated that the infusion temperature of the intraperitoneal chemotherapy solution(s) was 42 °C.…”

Section: Intraoperative Intraperitoneal Chemotherapy With Hyperthermia -Hipecmentioning

confidence: 99%

Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?

Crestani¹,

Benoit²,

Touboul³

et al. 2020

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become over years an effective strategy for the treatment of cancers with PM, initially in the treatment of primitive peritoneal tumors [mesothelioma (7) and pseudomyxoma peritonei (8)], later on, the advanced stages of ovarian cancer (9), and more recently has been applied in selected center even for the treatment of gastrointestinal tumor with PM (10,11). The application of CRS and HIPEC to CCA with PM (12, 13) has been described in a few cases with better results compared to SC in terms of overall survival.…”

Section: Introductionmentioning

confidence: 99%

Case Report: Cytoreductive Surgery and HIPEC Associated With Liver Electrochemotherapy in a Cholangiocarcinoma Patient With Peritoneal Carcinomatosis and Liver Metastasis Case Report

et al. 2021

View full text Add to dashboard Cite

Introduction: Cholangiocarcinoma (CCA) is the second most common primary tumor of the liver, and the recurrence after hepatic resection (HR), the only curative therapy, is linked with a worse prognosis. Systemic chemotherapy (SC) and liver loco-regional treatments, like trans-arterial chemoembolization (TACE) or radio embolization (TARE), have been employed for the treatment of unresectable intrahepatic metastasis (IM) with benefit on overall survival (OS), but SC has a limited effect on peritoneal metastasis (PM). In the last years, novel treatments like electrochemotherapy (ECT) with bleomycine (BLM) for IM and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS and HIPEC) for PM have been applied in small series but with encouraging results. We hereby describe the first synchronous application of ECT and CRS and HIPEC for the treatment of a patient with IM and PM from CCA.Case Description: A 47-year-old male patient with CCA underwent HR followed by adjuvant SC. After 14 months, for the occurrence of IM, the patient underwent a second HR and SC. Nonetheless, a new recurrence occurred and a third attempt of HR was proposed. Due to the intraoperative finding of unresectable IM with PM, no resective procedure was performed and the patient was referred to our center. CRS and HIPEC with cisplatin and mitomycin for PM and ECT with BLM on a bulky metastasis of the hepatic hilum were performed after 38 months from the first HR. The length of hospital stay was 19 days. At the computed tomography (CT) performed 11 days after treatment complete necrosis of the treated IM was detected.Results: CT scan after 3 and 6 months and magnetic resonance after 9 months were performed. Necrosis of the treated IM nor PM but progression of the residual liver lesions was observed. After 3 months, the patient received SC and underwent TACE after 8 months and TARE after 9 months for the residual liver metastases. At 14 months from CRS and HIPEC, the patient is alive, in good condition, and with stability of the disease.Conclusions: The association of ECT and CRS and HIPEC could be safe and effective for the treatment of unresectable recurrent intrahepatic CCA with PM.

show abstract

Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey

Cited by 17 publications

References 28 publications

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?

Case Report: Cytoreductive Surgery and HIPEC Associated With Liver Electrochemotherapy in a Cholangiocarcinoma Patient With Peritoneal Carcinomatosis and Liver Metastasis Case Report

Contact Info

Product

Resources

About